Governments should protect public-health policy from tobacco industry influence. Lobbying should be visible. Conflicts of interest should be declared and managed. Tobacco companies should not be allowed to write the rules intended to reduce the harm caused by their products.
None of that should be controversial.
But there is another principle worth defending just as firmly: the possibility that influence could occur is not proof that it caused a particular decision.
That distinction matters whenever tobacco policy is debated. It matters especially when disagreement over harm reduction becomes entangled with accusations about whose interests an argument might serve.
A policy can benefit a company and still benefit public health. A government can make a bad decision without having been captured. And a critic can disagree with a tobacco-control proposal without acting on behalf of the tobacco industry.
Each claim requires its own evidence.
A recent study in Tobacco Control provides a useful starting point. Researchers examined New Zealand’s implementation of Article 5.3 of the World Health Organization’s Framework Convention on Tobacco Control. They interviewed 21 people, including current and former politicians, officials, political journalists and public-health experts, and analysed key texts.
The published abstract reports poor awareness of Article 5.3 among politicians, limited guidance on industry interactions and weaknesses in lobbying oversight. Its conclusion is that inadequate implementation leaves New Zealand’s health policies vulnerable to tobacco industry interference. Read the study’s abstract.
But vulnerability is a different claim from demonstrated capture. The abstract itself makes the more limited claim. Discussion of the research should preserve that distinction.
There is also no need to dismiss the study because it involved 21 interviews. Qualitative research can reveal how institutions operate, identify gaps in accountability and uncover information that a large survey would miss. Interviews and documents can provide powerful evidence of influence.
The question is what the evidence establishes.
An interviewee describing a meeting they attended is providing a different kind of evidence from an interviewee expressing a general suspicion. A document recording an industry request shows what a company wanted. Establishing that the request shaped a government decision requires further examination.
Those distinctions should remain visible when research enters political debate.
If the allegation is that industry lobbying caused a particular policy change, we should ask what connects the lobbying to the outcome. What communications took place? Who had access? What advice reached decision-makers? Did a proposal change after an intervention? How convincing are alternative explanations?
There need not be a single incriminating email. Influence can be established through a combination of documents, testimony and a clear sequence of events.
But a policy outcome that an industry welcomes does not, by itself, establish that the industry caused it.
Alignment of interests is a reason to investigate. It is not a completed investigation.
The same discipline applies in the other direction. Failure to demonstrate capture does not establish that no influence occurred. Poor transparency can make influence difficult to trace. Uncertainty should prompt better disclosure and closer scrutiny, rather than confident declarations of either guilt or innocence.
This is where Article 5.3 has an important role.
It requires governments to protect tobacco-control policy from the tobacco industry’s commercial and other vested interests. Its implementation guidelines go beyond disclosure: they recommend limiting interactions to those strictly necessary for regulation, making necessary interactions transparent, avoiding conflicts and rejecting policy partnerships with the industry. WHO implementation guidelines.
These are preventive safeguards. Governments do not have to wait until someone proves that a decision was corrupted before putting them in place.
We can therefore support stronger protections while insisting on careful language about particular allegations. The evidence needed to justify a safeguard is different from the evidence needed to attribute a specific decision to industry pressure.
My concern is what happens when that distinction disappears and when scrutiny of corporate involvement slides into dismissal of the argument itself.
Consider vaping.
If someone argues that nicotine vaping can help adults stop smoking, the first substantive question should be whether the evidence supports that claim.
Cochrane’s living systematic review finds high-certainty evidence that nicotine e-cigarettes increase smoking quit rates compared with nicotine replacement therapy. The review also makes clear that longer and larger studies are needed to evaluate safety fully. Both findings belong in an honest discussion. Cochrane review.
New Zealand’s Ministry of Health recognises that vaping products, particularly those containing nicotine, may help some people stop smoking. It also advises against vaping for children, young people and people who do not smoke. Its cessation guidance describes vaping as less harmful than smoking, while making clear that it is not harmless. Ministry of Health report, smoking-cessation guidance.
These positions can coexist. Helping adults move away from cigarettes and preventing young people from taking up vaping are both legitimate public-health objectives.
None of this proves that every policy promoted as “harm reduction” is sound. Evidence about nicotine vaping does not automatically validate heated tobacco products, every tax concession or a particular marketing regime. Each proposal needs to be assessed on its own merits.
But the reverse is equally important. A tobacco company’s support for a proposal does not invalidate independent evidence supporting some part of it.
Commercial interests matter when evaluating the credibility of a source. Funding can affect which questions get researched, which findings get promoted and which uncertainties get overlooked. Disclosure should lead to closer examination of methods, selective reporting and independent replication.
It should not become a shortcut that allows us to avoid examining those things.
The proper response to an industry-funded claim is rigorous scrutiny. The proper response to an independently supported finding is not to discard it because an industry spokesperson has repeated it.
Nor does accepting a scientific finding require giving a company privileged access to ministers or a role in drafting policy. Governments can assess evidence independently while maintaining firm boundaries around commercial involvement.
That is why I favour broad transparency.
We should know who is lobbying, who pays them, which interests they represent and what they are asking the government to do. Relevant funding and conflicts should be disclosed by commercial organisations, advocacy groups and researchers.
This does not mean every organisation presents the same risks. A tobacco manufacturer and a public-health charity have different purposes and incentives. Broad disclosure can coexist with stronger safeguards for an industry whose interests warrant particular scrutiny.
The point is to make the evidence and the relationships easier to examine.
Public-health advocates should also expect their preferred policies to face questions. Whether a measure works, whom it helps, what unintended effects it creates and whether another approach could achieve more are legitimate subjects for debate.
An allegation about a critic’s relationships may warrant investigation. It does not answer those policy questions.
The standard I want is straightforward: strong safeguards, open records, independent evaluation and claims proportionate to the evidence.
If there is evidence of interference, present it. If the evidence establishes vulnerability, say so and close the gaps. If a policy is ineffective, explain why. If an argument is wrong, show where it fails.
Protecting public health from corporate influence is essential. Protecting public-health policies from legitimate criticism is something else entirely.
Article 5.3 should help protect evidence-based policymaking.
It should never replace it.
Tobacco control have made an art form of dishonesty. This is seen as clearly as daylight in the way Article 5.3 of the Framework Convention on Tobacco Control is used by them to deter supporters of tobacco harm reduction from speaking out. Article 5.3, as Alan Gor points out, is quite reasonable but it is the guidelines to Article 5.3, which were written later, and how the guidelines are used, or really mis-used, that are outrageous. People following this conflict will have noticed that the holy grail of Article 5.3 is mentioned twenty times more often than Article 1 (d) which endorses supply reduction, demand reduction AND harm reduction. Tobacco control zealots even go so far as to say that support for harm reduction is aligned with ‘the industry narrative’ and then insinuate that surreptitious money must have changed hands somewhere, somehow. My own involvement in tobacco harm reduction was in planning for a 1992 international harm reduction conference when I ensured that Professor Michael Russell was invited to speak in Melbourne on the subject of tobacco harm reduction. It’s hard to avoid the strong suspicion that tobacco control uses Article 5.3 and it’s guidelines to distract from their painfully weak arguments and contradictions. Their obsession with evil Big Tobacco becomes weaker every year as the transformation of tobacco companies from combustible cigarettes to safer nicotine products passes major milestones and accelerates. The two largest traded tobacco companies earned zero from safer nicotine products in 2014 but by 2025, safer nicotine products accounted for 42% of PMI’s and 18% of BAT’s revenue. The other side of the coin is that most tobacco control activists benefit from government or Bloomberg funding or other supports when the funding bodies are avid opponents of tobacco harm reduction. Where is the pressure for tobacco control to declare their funding sources? Somewhere forgotten in all this murk is the fact that smoking still causes huge numbers of cases of cancer, heart disease and respiratory conditions which often cause death. And yet we have much safer ways for people to consume nicotine today which are inexplicably blocked by tobacco control. Great that we now have more people with lived experience, including Alan Gor, pointing out these insanities.
If New Zealand's tobacco control policies have been significantly influenced by the tobacco industry, where is the evidence in the policy outcomes? After decades of declining smoking prevalence and increasingly restrictive tobacco regulation, the case for industry capture requires considerably stronger evidence than the study presently provides.